✦ LIBER ✦

A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin™) in mild Alzheimer's disease patients

✍ Scribed by M Grundman; E Capparelli; H.T Kim; J.C Morris; M Farlow; E.H Rubin; J Heidebrink; A Hake; G Ho; A.N Schultz; K Schafer; W Houston; R Thomas; L.J Thal

Book ID: 117174154
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 258 KB
Volume: 73
Category: Article
ISSN: 0024-3205
DOI: 10.1016/s0024-3205(03)00320-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A long-term, double-blind, placebo-contr

A long-term, double-blind, placebo-controlled efficacy and safety study of nicergoline in patients with mild to moderate Alzheimer's disease

✍ L. Amaducci; K. Maurer; B. Winblad; R. Dom; R. Bullock; L. Bonura; A. Battaglia; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 291 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

Saffron in the treatment of patients wit

Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial

✍ S. Akhondzadeh; M. Shafiee Sabet; M. H. Harirchian; M. Togha; H. Cheraghmakani; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Efficacy and safety of donepezil in pati

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

✍ Howard Feldman; Serge Gauthier; Jane Hecker; Bruno Vellas; Yikang Xu; John R. Ie 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 634 KB

## Abstract ## Background There have been very limited investigations of cholinesterase inhibitor therapy in more advanced stages of Alzheimer's disease (AD). The efficacy and safety of donepezil were evaluated in __post hoc__ analyses of a subgroup of patients with more severe AD (standardized Mi

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting

✍ Pierre N. Tariot; Jeffrey L. Cummings; Ira R. Katz; Jacobo Mintzer; Carlos A. Pe 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB

Safety of entacapone and apomorphine coa

Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study

✍ Jan C.M. Zijlmans; Berengere Debilly; Olivier Rascol; Andrew J. Lees; Franck Dur 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract We investigated whether administration of the catechol‐__O__‐methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamic